Figure 2 | Scientific Reports

Figure 2

From: Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP

Figure 2

In vivo GaTate PET imaging phenotype and LuTate response across the tumour panel. (a) Mice bearing subcutaneous tumours were imaged using a small animal PET scanner following administration of GaTate (Images shown in Supp. Figure 1). PET tracer tumour to background uptake ratios were determined and are expressed as mean ± SEM of at least three independent tumours. (b) Mice bearing tumours were treated intravenously with saline or 20 MBq LuTate on day 1. Tumour volumes are expressed as mean ± SEM of 4–8 animals/group.

Back to article page